Hypochondroplasia clinical trials at UCSF

4 in progress, 2 open to eligible people

Hypochondroplasia is a genetic disorder that affects bone growth. UCSF is conducting studies to track how children with this condition grow over time. Researchers are gathering detailed measurements of children's growth and health in these observational studies.

Showing trials for

  • Multinational Observational Study of Children With Hypochondroplasia

    open to eligible people ages up to 15 years

    This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.

    Oakland 5378538, California 5332921 and other locations

  • Clinical Assessment Study in Children With Hypochondroplasia

    open to eligible people ages 30 months to 16 years

    This is a long-term, multicenter, non-interventional study of children ages 2.5 to <17 years with hypochondroplasia (HCH).

    Oakland 5378538, California 5332921 and other locations

  • Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months

    Sorry, not currently recruiting here

    The purpose of this study is to evaluate the safety and efficacy of daily administration of vosoritide in participants with HCH aged 0 to < 36 months over a 52-week period.

    Oakland 5378538, California 5332921 and other locations

  • Interventional Study of Infigratinib in Children With Hypochondroplasia

    Sorry, accepting new patients by invitation only

    ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety, of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib, at one of two doses, of who have completed at least 26 weeks of participation in QED-sponsored ACCEL (QBGJ398-004).

    Oakland 5378538, California 5332921 and other locations

Last updated: